Search hospitals

>

Texas

>

Longview

Texas Oncology-Longview Cancer Center

Claim this profile

Longview, Texas 75601

Global Leader in Breast Cancer

Global Leader in Lung Cancer

Conducts research for Prostate Cancer

Conducts research for Pancreatic Cancer

Conducts research for Cancer

53 reported clinical trials

2 medical researchers

Photo of Texas Oncology-Longview Cancer Center in LongviewPhoto of Texas Oncology-Longview Cancer Center in LongviewPhoto of Texas Oncology-Longview Cancer Center in Longview

Summary

Texas Oncology-Longview Cancer Center is a medical facility located in Longview, Texas. This center is recognized for care of Breast Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer, Cancer and other specialties. Texas Oncology-Longview Cancer Center is involved with conducting 53 clinical trials across 80 conditions. There are 2 research doctors associated with this hospital, such as Donald A. Richards and Lijo John, MD.

Area of expertise

1

Breast Cancer

Global Leader

Texas Oncology-Longview Cancer Center has run 19 trials for Breast Cancer. Some of their research focus areas include:

Stage IV
HER2 negative
Stage III
2

Lung Cancer

Global Leader

Texas Oncology-Longview Cancer Center has run 11 trials for Lung Cancer. Some of their research focus areas include:

PALB2 positive
Stage IV
Stage III

Top PIs

Donald A. Richards

Texas Oncology - Tyler

6 years of reported clinical research

Expert in Cancer
Studies Breast Cancer
44 reported clinical trials
72 drugs studied

Lijo John, MD

Texas Oncology - Longview Cancer Center

13 years of reported clinical research

Studies Bladder Cancer
Studies Central Nervous System Hodgkin Lymphoma
4 reported clinical trials
10 drugs studied

Clinical Trials running at Texas Oncology-Longview Cancer Center

Follicular Lymphoma

Marginal Zone Lymphoma

MALT Lymphoma

Image of trial facility.

Zanubrutinib + Anti-CD20

for Lymphoma

The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R\^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free survival as determined by an independent review committee in accordance with the 2014 modification of the International Working Group on non-Hodgkin lymphoma (NHL) Criteria based on n positron emission tomography and computed tomography (PET/CT), and to compare the efficacy of zanubrutinib plus rituximab versus R\^2 in participants with R/R marginal zone lymphoma (MZL), as measured by progression free survival (PFS) assessed by IRC in accordance with CT-based Lugano 2014 Criteria.

Recruiting

2 awards

Phase 3

5 criteria

Similar Hospitals nearby

Select from list below to view details

Frequently asked questions

What kind of research happens at Texas Oncology-Longview Cancer Center?

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.